SOPs for Drug Discovery

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for evaluating potential drug-drug interactions (DDIs) in preclinical models. Understanding DDIs is crucial to assess the safety, efficacy, and pharmacokinetic behavior of drug candidates, particularly in combination therapies. This SOP ensures standardized methods for studying DDIs, providing reliable data on the effects of concurrent drug administration on absorption, distribution, metabolism, and excretion (ADME) properties of the drugs.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the methodology for establishing dose-response curves in preclinical studies. Dose-response curves are essential in determining the relationship between the dose of a drug candidate and its pharmacological effect. This SOP ensures that dose-response studies are conducted in a standardized manner, providing reliable data to help identify the effective dose range, therapeutic window, and potential toxicities of a compound.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for conducting behavioral studies in animal models. Behavioral studies are essential in preclinical research to evaluate the impact of drug candidates or experimental treatments on cognitive function, emotional responses, and motor behavior. This SOP ensures that behavioral studies are conducted systematically, ethically, and in compliance with regulatory standards, providing reliable data on the effects of treatments on animal behavior.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for evaluating the anti-inflammatory properties of drug candidates in preclinical animal models. Anti-inflammatory testing is crucial to assess the potential of drug candidates to reduce or modulate inflammatory responses associated with diseases such as arthritis, asthma, or other chronic inflammatory conditions. This SOP ensures standardized methods for assessing anti-inflammatory efficacy, providing consistent and reproducible data that support the clinical development of therapeutic agents.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the methodology for conducting neurotoxicity screening in preclinical animal models. Neurotoxicity testing is essential for evaluating the potential effects of drug candidates or chemicals on the nervous system, which may lead to motor dysfunction, cognitive impairments, or behavioral changes. This SOP ensures that neurotoxicity studies are performed consistently, accurately, and in compliance with regulatory standards, providing critical safety data for clinical development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for conducting allergenicity testing in preclinical studies. Allergenicity testing is essential for evaluating the potential of drug candidates or other substances to cause allergic reactions, including skin sensitization and respiratory hypersensitivity. This SOP ensures that allergenicity studies are performed consistently, accurately, and in compliance with regulatory standards, providing data to assess the safety of compounds and their potential to induce allergic reactions in humans.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for performing immunotoxicity testing in preclinical studies. Immunotoxicity testing is essential for assessing the potential effects of drug candidates on the immune system, which may lead to adverse effects such as immunosuppression, allergic reactions, or autoimmunity. This SOP ensures that immunotoxicity studies are performed in compliance with regulatory standards and that results are obtained with high consistency and reproducibility.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the methodology for conducting biochemical analysis in preclinical studies. Biochemical analysis is essential for evaluating the effects of drug candidates on various biochemical markers, enzymes, metabolites, and other molecular targets. This SOP ensures that biochemical analyses are performed consistently, accurately, and in compliance with regulatory standards, providing valuable insights into the therapeutic potential or toxicity of a compound.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedure for conducting hematological analysis in preclinical studies. Hematological analysis is crucial in evaluating the effects of drug candidates on blood parameters, including red and white blood cells, hemoglobin levels, platelet count, and other markers. This SOP ensures that hematological tests are conducted consistently and in compliance with regulatory standards, providing reliable data for assessing the safety and efficacy of potential therapeutic agents.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the procedures for preparing tissue samples for histopathological analysis. Histopathological analysis is essential for evaluating the effects of drug candidates, treatments, or disease processes on tissues and organs. This SOP ensures standardized methods for tissue collection, fixation, embedding, sectioning, and staining to obtain high-quality slides suitable for microscopic evaluation.
Click to read the full article.